Award
NIH Reporter #5P30CA016359-46
Developmental Therapeutics Research Program
Recipient
Yale University
Award Amount
$69,205.00
Ceiling
$69,205.00
Awarded
September 16, 2026
Identifier
5P30CA016359-46
Yale University received a research grant from the National Cancer Institute to support the Developmental Therapeutics Research Program, focusing on translational cancer therapeutics and novel therapy trials.
Description
The Developmental Therapeutics (DT) Research Program at Yale Cancer Center is a translational hub bridging drug discovery and therapeutics to translate preclinical findings into patient treatments. The program focuses on targets like p53, RAS, MYC, and immunotherapy-resistant cancers, and conducts rational trials of novel therapies. It emphasizes collaboration across disciplines, molecular profiling, chemical biology, and immunotherapy. The program includes resources like the Early Phase Clinical Trials Network and has 59 members from 16 departments. Total cancer-related funding is $23.4M, with $7.9M peer-reviewed, including $4.4M from NCI. The program has published 806 papers, with a focus on advancing cancer therapeutics.